MedImmune, the global biologics R&D arm of AstraZeneca, and 3M Drug Delivery Systems, have entered research collaboration to develop next generation toll-like receptor (TLR) agonists that activate innate immune cells and enhance the visibility of cancer tumors.   MedImmune has in-licensed 3M’s MEDI9197, a novel TLR 7/8 dual agonist entering Phase I development to explore the safety and tolerability of MEDI9197 as a potential treatment for patients with solid tumors.   MEDI9197 has been d...